Sinobot and China MediLife Forge Strategic Alliance to Build the 'Da Vinci of Neurosurgery'; IPO Filing Submitted

VCBeat (WeChat ID: vcbeat) has learned that in September 2019, Sinovation Medical Technology Co., Ltd. and China-United States Mutual Benefit Medical Co., Ltd. signed a strategic cooperation agreement in Beijing. The two parties aim to become “core strategic partners” through this agreement, collaborating across the vertical upstream and downstream industry chains and horizontally in market and customer resources. They will share advanced technologies, innovate business models, and foster an ecosystem for innovative medical devices, providing domestic healthcare institutions with innovative medical device products and services such as neurosurgical robots and neurosurgical navigation systems.

Wang Ke, General Manager of Sinovation, stated that both Sinovation and China Medical Technologies are committed to providing high-quality healthcare-related technologies, products, and services to the medical profession in China. China Medical Technologies brings extensive experience in the marketing and technical support of surgical robots, while Sinovation offers superior product and service capabilities. This strategic partnership will inject vitality into the development of China’s domestic surgical robot industry, facilitating healthcare transformation and enhancing clinical efficiency.

Mr. Liu Yi, Vice President of Fosun Pharma and CEO of China-U.S. United Medical Services Holding Corporation (CUMC), stated that Sinovation’s outstanding innovation capabilities in intelligent healthcare, along with its high-quality surgical robots and surgical navigation products, were key drivers for the partnership. By pooling the expertise of clinical specialists, both parties aim to translate world-class technologies into clinical applications, thereby enhancing the trustworthiness of innovative medical devices in China.

Sinovation specializes in medical robotics technology and the innovation of intelligent medical products. The company’s team began research, development, and testing of medical navigation robot technology in collaboration with Tsinghua University as early as 2006, and has currently established collaborations related to medical navigation robot technology with more than 100 Grade-A tertiary hospitals across China. Sinovation’s neurosurgical robotic system is China’s first innovative neurosurgical robot, enabling physicians to rapidly localize lesions, formulate surgical plans, and provide fast surgical guidance while effectively avoiding intracranial blood vessels and critical functional areas. Sinovation’s neurosurgical navigation system leverages high-precision, high-sensitivity real-time localization and tracking technology, along with bidirectional projection mixed reality (MR) technology, to provide multidimensional visualization, tracking, and guidance during craniotomy for intracranial hemorrhage, residual tumor tissue, epileptic foci, brain functional areas, and neural activity information.

As a key member of Fosun Pharma’s Medical Devices Division, China United Medical Exchange Co., Ltd. has been committed to advancing the development of medical devices in China. As a leading medical equipment supplier and practitioner in China’s medical device industry, the company is dedicated to providing high-quality healthcare-related technologies, products, and services to the global healthcare sector. From 2004 to 2018, serving as the exclusive distributor for Intuitive Surgical in mainland China and Hong Kong, it made outstanding contributions to the development of the da Vinci Surgical System in China. Subsequently, Fosun Pharma, the parent company of China United Medical Exchange, jointly established a new joint venture with Intuitive Surgical named Intuitive Fosun. Since 2019, the da Vinci Surgical System business has been operated under this new platform.